During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 2.36 million, with the beta value of the company hitting 2.23. At the end of the trading day, the stock’s price was $0.62, reflecting an intraday gain of 15.74% or $0.08. The 52-week high for the ADAP share is $2.05, that puts it down -230.65 from that peak though still a striking 14.52% gain since the share price plummeted to a 52-week low of $0.53. The company’s market capitalization is $159.54M, and the average intraday trading volume over the past 10 days was 3.15 million shares, and the average trade volume was 2.05 million shares over the past three months.
Adaptimmune Therapeutics Plc ADR (ADAP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.89. ADAP has a Sell rating from 1 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Adaptimmune Therapeutics Plc ADR (ADAP) registered a 15.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 15.74% in intraday trading to $0.62, hitting a weekly high. The stock’s 5-day price performance is 7.72%, and it has moved by -13.79% in 30 days. Based on these gigs, the overall price performance for the year is -16.42%. The short interest in Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is 5.35 million shares and it means that shorts have 4.71 day(s) to cover.
The consensus price target of analysts on Wall Street is $4, which implies an increase of 84.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $4 respectively. As a result, ADAP is trading at a discount of -545.16% off the target high and -545.16% off the low.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Statistics show that Adaptimmune Therapeutics Plc ADR has outperformed its competitors in share price, compared to the industry in which it operates. Adaptimmune Therapeutics Plc ADR (ADAP) shares have gone down -38.87% during the last six months, with a year-to-date growth rate more than the industry average at 77.78% against 16.70.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.30%. While earnings are projected to return 71.06% in 2025.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Adaptimmune Therapeutics Plc ADR insiders own 0.38% of total outstanding shares while institutional holders control 60.27%, with the float percentage being 60.49%. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the largest shareholder of the company, while 95.0 institutions own stock in it. As of 2024-06-30, the company held over 38.97 million shares (or 16.1135% of all shares), a total value of $38.0 million in shares.
The next largest institutional holding, with 27.4 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 11.3299% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $26.72 million.
